Every founder in the beauty space wants their product to stand out, and bold marketing language feels like the fastest route there. But in cosmetics, word choice is not just a branding decision — it is a regulatory one. The Food and Drug Administration does not classify your product based on what is in the bottle. It classifies your product based on what you say about it. Say the wrong thing, and your lightweight serum can legally become an "unapproved new drug" overnight, regardless of the formula inside.
For startup and indie brands operating on lean budgets and fast launch timelines, this distinction is one of the most consequential — and most commonly misunderstood — compliance risks in the industry.
The Legal Line Between Cosmetics and Drugs
Under the Federal Food, Drug, and Cosmetic Act (FDCA), a cosmetic is a product intended to cleanse, beautify, promote attractiveness, or alter appearance. A drug, by contrast, is a product intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body.
Notice the operative word in both definitions: intended. The FDA does not primarily look at your ingredient list to decide which category you fall into. It looks at "intended use," which the agency determines from your labeling, website copy, social media posts, influencer partnerships, and even consumer-facing packaging inserts.
This means two nearly identical moisturizers — same formula, same INCI list — can be regulated completely differently depending entirely on how they are marketed.
How Marketing Claims Trigger Drug Status
The most frequent compliance trap for indie brands is the unintentional use of therapeutic or physiological language. Claims that cross the line typically fall into a few recognizable categories:
- Disease-related claims — "treats acne," "heals eczema," "cures rosacea"
- Structure/function claims — "stimulates collagen production," "regenerates skin cells," "repairs damaged tissue"
- Anti-inflammatory or medicinal claims — "reduces inflammation," "accelerates wound healing"
- Hormonal or physiological claims — "balances hormones," "detoxifies the body"
- Comparative therapeutic claims — "works like Retin-A," "clinical-grade alternative to prescription treatment"
Each of these statements implies that the product changes how the body functions biologically, not merely how it appears. That shift in implication is enough for the FDA to treat the product as a drug — which means it now needs either FDA approval through a New Drug Application, or compliance with an applicable Over-the-Counter (OTC) drug monograph (as exists for sunscreens, antiperspirants, and anti-dandruff shampoos, for example).
Most indie brands have neither the budget nor the clinical infrastructure to meet those requirements. The practical consequence is a warning letter, a required product reformulation or relabeling, and in some cases a halted product line.
Why "Appearance Of" Language Matters
The safer, FDA-recognized path is cosmetic-appropriate language that describes appearance rather than physiological change. Compare:
-
Drug-triggering: "Stimulates new collagen synthesis to repair skin."
-
Cosmetic-safe: "Improves the appearance of fine lines and firmness."
-
Drug-triggering: "Treats and clears acne breakouts."
-
Cosmetic-safe: "Helps reduce the appearance of blemishes."
This is not semantic gamesmanship — it reflects a legally meaningful distinction. "Appearance of" claims describe a cosmetic effect. Claims describing cellular, hormonal, or disease-related outcomes describe a drug effect, even if the active ingredient is identical in both bottles.
MoCRA Adds a New Layer of Scrutiny
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly expanded FDA oversight of cosmetics, and it raises the stakes for misclassification. Under MoCRA, cosmetic companies must now:
- Register manufacturing facilities with the FDA
- List each product and its ingredients with the agency
- Designate a "Responsible Person" accountable for safety
- Maintain safety substantiation records for every product
- Report serious adverse events to the FDA within 15 business days
- Comply with Good Manufacturing Practice requirements once finalized
MoCRA did not change the cosmetic/drug distinction itself, but it did give the FDA new recordkeeping, inspection, and recall authority specifically over cosmetics. That means your marketing claims are now more likely to be reviewed in connection with a broader compliance file the agency already has on your brand — facility registration, product listings, and safety data included. A drug-claim violation no longer exists in isolation; it surfaces alongside your entire MoCRA compliance posture.
Practical Steps Before You Launch
Founders should treat marketing language as a compliance deliverable, not just a creative one. Before launch, or before any new campaign:
- Audit every claim on packaging, your website, Amazon listings, and social media captions — including claims made by influencers or affiliates on your behalf.
- Avoid medical or clinical terminology such as "treats," "cures," "heals," "anti-inflammatory," or references to named skin conditions.
- Reframe benefit language around appearance, texture, and sensory experience rather than biological mechanism.
- Scrutinize "clean," "clinical," and "dermatologist-tested" claims, which carry their own substantiation requirements even outside the drug/cosmetic question.
- Review influencer and UGC content before reposting it — the FDA treats brand-controlled repostings as your own marketing claims.
- Build a documented safety substantiation file now, since MoCRA requires it regardless of your claims strategy.
The Bottom Line for Founders
The cosmetic-versus-drug line is not about ingredients — it is about language. A single phrase in your product description or Instagram caption can shift your entire regulatory category, exposing your brand to enforcement action you never anticipated. Combined with MoCRA's new registration, listing, and safety substantiation requirements, marketing claims are no longer just a branding choice; they are a legal exposure point.
Before your next launch, campaign refresh, or influencer partnership goes live, a legal claims review is one of the highest-leverage compliance investments a cosmetic founder can make.